Syed Abutalib
Hematology & Oncology · Milwaukee, WINPI 1114183290
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,690 of the $153,537 with a category attached, or 60.4%. AstraZeneca accounts for 68.2% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $37,131 and has fallen 57.8% since, to $15,671 in 2025. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $577.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$105K
- ADC Therapeutics America, Inc.$10K
- Incyte Corporation$4K
- Verastem, Inc.$4K
- Partner Therapeutics, Inc.$4K
- Pfizer$4K
- plus $22K from 32 others
Across 1 payment — averaging $9800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$10K
What the payments were for
- Consulting fees$39,70426%
- Speaking & faculty fees$92,69060%
- Travel & lodging$13,9929%
- Food & beverage$6,8674%
- Education$2830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $104,753 |
| ADC Therapeutics America, Inc. | 6 | $10,228 |
| Incyte Corporation | 5 | $4,351 |
| Verastem, Inc. | 6 | $4,167 |
| Partner Therapeutics, Inc. | 5 | $4,044 |
| Pfizer | 34 | $4,021 |
| Geron Corporation | 9 | $3,788 |
| Jazz Pharmaceuticals Inc. | 10 | $3,368 |
| Epizyme, Inc. | 3 | $3,262 |
| Syndax Pharmaceuticals, Inc. | 5 | $3,201 |
| Agios Pharmaceuticals, Inc. | 1 | $2,800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $2,743 |
| Seagen Inc. | 9 | $405 |
| Novartis | 16 | $333 |
| Johnson & Johnson | 16 | $301 |
| Beigene USA, Inc. | 4 | $276 |
| Astellas Pharma US Inc | 9 | $199 |
| Bristol Myers Squibb | 8 | $196 |
| E.r. Squibb & Sons, L.L.C. | 3 | $172 |
| Bayer | 4 | $156 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $85 |
| Merck | 5 | $67 |
| Genentech USA, Inc. | 3 | $61 |
| Adaptive Biotechnologies Corporation | 1 | $57 |
| Amgen | 2 | $53 |
| Secura Bio, Inc. | 1 | $45 |
| Sanofi | 2 | $40 |
| AbbVie | 2 | $39 |
| CTI Biopharma Corp. | 2 | $38 |
| Aurobindo Pharma USA, Inc. | 2 | $34 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Morphosys, US Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,537 in reported general payments places this provider in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 11 | $183,777 |
| Posaconazole | 33 | $42,664 |
| EliquisApixaban | 33 | $21,985 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 11 | $1,785 |
| Dapsone | 34 | $1,508 |
| Tacrolimus | 16 | $1,474 |
| PediarixHep B Vaccine/Dp(A)t-Polio/Pf | 13 | $1,347 |
| ValacyclovirValacyclovir Hcl | 42 | $1,122 |
| Fluconazole | 20 | $900 |
| Cefdinir | 11 | $859 |
| Hydroxyurea | 29 | $641 |
| PedvaxhibHaemph B Polysac Conj-Menin/Pf | 13 | $540 |
| Acyclovir | 37 | $434 |
| Prednisone | 43 | $274 |
| Levofloxacin | 29 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $4,351 | $183,77711 claims |
| PfizerEliquis | $4,021 | $21,98533 claims |
| MerckPedvaxhib | $67 | $54013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
- Renju Vechurettu RajMilwaukee$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.